Vanguard Asset Management
SANA icon

Vanguard Asset Management’s Sana Biotechnology SANA Stock Holding History

Vanguard Asset Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Hold
101,668
– – ﹤0.01% 2305
2026
Q1 		$293K Buy
+101,668
New +$400K ﹤0.01% 2299

Other funds holding SANA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Asset Management's SANA Position: Q2 2026 in Review

Vanguard Asset Management held its Sana Biotechnology (SANA) position steady in Q2 2026 at 101,668 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Vanguard Asset Management first reported a position in SANA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Vanguard Asset Management held 101,668 shares of Sana Biotechnology worth $355K as of Q2 2026.
  • Vanguard Asset Management left its Sana Biotechnology share count unchanged in Q2 2026.
  • Sana Biotechnology made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2305 holding.
  • Vanguard Asset Management first reported a position in Sana Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.